SynthesisFrontiers in neurology2025
Clinical efficacy of edaravone dexborneol in the treatment of acute ischemic stroke: meta-analysis.
Synthesis in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Edaravone dexborneol in acute ischemic stroke: a systematic review and meta-analysis of randomized trials with clinical and thrombectomy-specific subgroup analyses.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Efficacy and safety of edaravone dexborneol for acute ischemic stroke: a meta-analysis.Frontiers in neurology · 2026Pooled it
- Intravenous Thrombolysis Preceding Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Reduces the Inflammatory Response: Preliminary Results Based on Retrospective Analysis of Medical Documentation.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In China, edaravone dexborneol (ED) is often used to treat acute ischemic stroke (AIS), but internationally, ED is not commonly used. This study aimed to conduct a meta-analysis on the application of ED in AIS, so as to provide reference and guidance for clinical use in the future. Methods: Pubmed and Web of Science databases were searched for articles on ED in the treatment of AIS. Two researchers independently searched the articles based on pre-specified inclusion (randomized controlled trial, complete data, correct logic, English literature, etc.) and exclusion criteria (studies lacking objective reference standards, studies with follow-up success rates below 80%, etc.), and duplicate articles were excluded using Endnote. The search was set for the build time to December 2024. Then, the initially enrolled articles were subjected to information and data extraction and crosschecking, followed by meta analysis using the RevMan 5.3 software after screening. Primary outcome measures included clinical efficacy, safety, and NIHSS. Results: A total of 5 articles were included after screening, totaling 2,651 study participants. Subjects in the 5 articles were divided into an experimental group (ED treatment, Conclusion: While ED demonstrates short-term efficacy in improving neurological outcomes, its clinical applicability remains uncertain due to unresolved questions about drug diffusion and delivery in human brain tissue, which may fundamentally limit its long-term benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.